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Role for "uremic toxin" in the progressive loss of intact nephrons in
chronic renal failure. We studied the effect on the progression of
glomerular sclerosis of two different experimental maneuvers, perito-
neal dialysis and oral adsorbent, which remove circulating substances
in different fashions. Munich-Wistar rats with established glomerular
sclerosis, verified by renal biopsy analysis at seven weeks after subtotal
nephrectomy, were treated for four weeks with either peritoneal
dialysis (PD) or oral charcoal adsorbent (AST-120). Treatment was
initiated at eight weeks. Rats were paired in treatment and control
groups according to the similarity in the degree of sclerosis determined
at biopsy with a minimum of 50 glomeruli analyzed. Systolic blood
pressure and BUN and creatinine clearance, measured at seven to eight
weeks, were not different among groups. In Group 2 rats, PD was
performed with 1.5% dextrose for eight one-hour cycles, six days per
week, while Group I control rats had zero indwelling time of the
dialysate. Group 4 rats received AST-120, an oral adsorbent charcoal,
mixed 5% by weight with standard rat chow and given ad libitum from
8 to 12 weeks after subtotal nephrectomy, while control Group 3 rats
received only rat chow. Whole kidney GFR at 12 weeks was signifi-
cantly higher in Group 2 PD versus Group 1 control (0.50 0.08 vs.
0.30 0.05 mI/mm, P < 0.05). There was no statistical difference for
BUN and whole kidney creatinine or inulin clearance in Group 4
AST-120 treated versus Group 3 control rats. Light microscopic studies
in autopsy specimens revealed that both PD and AST- 120 attenuated
progression of glomerular sclerosis. Thus, at autopsy, the sclerosis
index averaged 1.78 0.21 versus 1.30 0.19 in Group I control and
Group 2 PD, respectively (P < 0.05), and 1.42 0.16 versus 0.99 0.13
in Group 3 control and Group 4 AST-120 treated rats, respectively (P <
0.05). Since the dialysis replaces primarily the filtration function of the
nephrons removed at the onset of the study, the present observations
support the possibility that the biologically-active circulating sub-
stances, or so-called uremic toxins", are involved in the advancement
of glomerular sclerosis and are ultrafiltrable in nature.
Nearly a quarter century ago Kurnick and Lindsey performed
a now classic experiment using a parabiotic mouse model [1].
Kidneys of a normal mouse connected in circulation with an
anephric mouse developed hypertrophy. These findings pro-
vided convincing evidence for the involvement of circulating
substances in compensatory renal hypertrophy. In experimen-
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tal animals in whom a large population of nephrons is removed,
a typical hypertrophy develops in remnant nephrons in associ-
ation with progressive destruction of the glomerular architec-
ture [2—51. The structural injury is characterized by accumula-
tion of mesangial matrix and relentless advancement of
glomerular sclerosis. Because this phenomenon occurs in oth-
erwise healthy remnant glomeruli, the notion has recently been
formulated that progressive glomerular sclerosis in the chroni-
cally failing kidney resulting from a variety of primary diseases
represents adaptive responses to reduced functioning nephrons
[61. The possibility that, like hypertrophy, this sclerosis process
may also involve circulating substances has been raised on the
basis of observations in human transplanted kidneys. Thus,
Pinto et al [7] noted that the incidence of recurrence of focal
glomerular sclerosis, a unique primary form of glomerular
sclerosis, in transplanted kidneys was unusually high, much
greater than the incidence of de novo focal glomerular sclerosis
in the general population or in kidney transplant recipients with
renal failure secondary to other causes. The authors speculated
that "some toxic circulating factor" could have lead to the
development of focal glomerular sclerosis.
If circulating substances indeed promote glomerular hyper-
trophy and sclerosis in chronic renal disease of other causes, as
well, these substances would represent a key mechanism com-
pleting the vicious cycle of progressive glomerular damage
leading to the end stage kidney (Fig. 1). Impaired renal function
due to glornerular sclerosis would result in the accumulation of
such circulating substances which, in turn, would promote
glomerular sclerosis by augmenting mesangial matrix accumu-
lation and obliteration of the glomerular capillary tuft.
In the present study, therefore, we examined the possibility
that the progressive glomerular sclerosis of remnant nephrons
indeed involves, at least in part, circulating substances. Al-
though still far from identifying the specific circulating sub-
stance(s) of interest, we sought to narrow the candidates by
characterizing the nature of such substances. For these rea-
sons, we employed two experimental maneuvers, peritoneal
dialysis and oral adsorbent administration, each of which re-
moves somewhat different classes of materials from the circu-
lation.
462 Motojima et a!: "Uremic toxin" in progressive kidney disease
Methods
Experimental groups
Studies were performed on four groups of adult male Munich-
Wistar rats, weighing 200 to 220 g, which were maintained on
standard laboratory rat chow. The experimental protocols
employed in the four groups are outlined in Figure 2. All
surgical procedures were performed under sterile conditions.
All rats were subjected to subtotal nephrectomy under pento-
barbital anesthesia (Nembutal, Abbott Laboratories, North
Chicago, Illinois, USA; 25 to 30 mg/kg body weight, i.p.).
Subtotal nephrectomy was performed by right nephrectomy
and ligation of two or three branches of the left renal artery by
silk ligature to leave approximately ¼ to '/s of total kidney mass.
Seven weeks after the nephrectomy, each rat underwent creat-
mine clearance (Car) measurement and renal biopsy.' Kidney
biopsy was performed as described by Adler et al [81. Briefly, a
small portion of the upper pole of the kidney was surgically
removed, and bleeding from the biopsy wound promptly con-
trolled with application of gelform (The Upjohn Company,
Kalamazoo, Michigan, USA). A guide tube for peritoneal
dialysis (PD) was surgically implanted at this time in Group 1
and 2 rats as described below. One week later, a four week
course of PD (Group 2) or sham procedure (Control:Group I)
was started. Group 1 rats were pair-fed with Group 2 rats using
the regimen described by us earlier [9].
Eight weeks after subtotal nephrectomy, oral charcoal adsor-
bent AST-l20 (Kureha Chemical Industry, Tokyo, Japan),
mixed with standard rat chow in 5% wt/wt, was given ad libitum
to Group 4 rats and continued for the remainder of the study.
Group 3 rats had free access to standard rat chow without
AST-120 and served as a control for Group 4.
At eight weeks, when each group of animals was placed on its
specified protocol, systolic blood pressure was measured in all
animals by the tail cuff method [10]. At ten weeks, measure-
ments of BUN and creatinine clearance were repeated. Upon
completion of study, at twelve weeks after subtotal nephrec-
tomy, the micropuncture measurements specified below were
performed on surface remnant nephrons in each rat. Animals
were then sacrificed with overdose anesthesia, and the kidneys
were removed for microscopic study.
Correlation between inulin and endogenous creatinine
clearance
To estimate whole kidney GFR through a non-invasive
procedure during the course of disease, endogenous creatinine
clearance was measured in awake rats in the current study. For
this purpose, the degree of correlation between endogenous
creatinine and inulin clearance in rats with remnant kidneys was
ascertained in a separate group of 29 subtotally nephrectomized
rats. Male Sprague-Dawley rats (220 to 330 g) were subjected to
subtotal nephrectomy by right nephrectomy and ligation with
silk ligature of branches of the left renal artery to remove renal
mass in various degrees. Within 60 days after nephrectomy, rats
with various BUN levels were placed in metabolic cages for
24-hour urine collection. Serum creatinine level was measured
immediately before and after the urine collection. Rats were
then anesthetized and subjected to C measurement as de-
scribed below. and C correlated closely with each other (r
= 0.966, P < 0.01; Fig. 3).
Implantation of guide tube
Animals with comparable whole kidney sclerosis index assessed on
biopsy specimens were paired, so that one was included in Group I and
its partner in Group 2. Likewise, one of a given pair was included in
Group 3, while its partner was in Group 4. Animals which did not have
a matching partner, that is, ones with sclerosis index values deviating
markedly from those of any others, were excluded from the study.
In Group I and Group 2 animals, chronic access to the
peritoneal cavity for peritoneal dialysis was established by
implantation of a silicone guide tube. Silicone (Medical Adhe-
sive Silicone Type A, Dow Corning Corp., Midland, Michigan,
USA) was solidified around a —15 cm-length silicone catheter
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Fig. 1. Schematic presentation of the hypothesis tested in the present
study. If circulating substances indeed promote accumulation of gb-
merular mesangial matrix (left side of circle) resulting in obliteration of
the glomerular capillary, the progressive fall in glomerular filtration
resulting from the glomerular sclerosis would, in turn, result in further
accumulation of such circulating substances. Thus, the vicious and
self-perpetuating cycle of progressive injury would be completed. The
present study examined whether removal of such circulating "uremic
toxins" (left inner arrow), via peritoneal dialysis or oral adsorbent
treatment could interrupt this chain of events.
Week
0 Subtotal nephrectomy
Creatinine clearance
7 Biopsy
(Guide tube implantation)
8
Group 1: PD control
GroUp 3: AST-120 control 10 Creatinine clearance
Group 4: AST-120
______
Inulin clearance
12 Micropuncture
Autopsy
Fig. 2. Schematic presentation of the experimental protocols em-
ployed in the four experimental groups.
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(I.D. 3.27 mm, O.D. 4.54 mm, Silastic Medical-Grade Tubing,
Dow Corning Corp.) to shape an oval disk (—3 x 2 cm, —2.5
mm thickness) at a distance —2 cm away from the edge of the
catheter. This constructed catheter and all surgical instruments
were sterilized by ethylene oxide gas. Rats were anesthetized
with sodium pentobarbital as for subtotal nephrectomy. Follow-
ing laparotomy through an approximately 6 cm-length midline
incision, the skin in the left lower quadrant area was separated
from the underlying fascia and muscle layer to allow subsequent
placement of the catheter disk on the outer surface of the
abdominal muscle wall. The constructed catheter was passed
under the skin and exteriorized at the back of the neck. The
disk-end of the catheter was then guided into the peritoneal
cavity through a —5 mm-diameter tunnel created by an electric
cautery at a site —2 cm left from midline. The catheter edge was
then cut to allow minimum exposure of the catheter to the
peritoneal cavity and firmly anchored on the inner surface of the
abdominal muscle wall with a 3-0 nylon suture. Several stitches
were then made with a 3-0 nylon suture around the silastic disc
to anchor the disc firmly on the outer surface of the abdominal
muscle wall. An occluding plastic obturator tube (Dobbhoff,
Biosearch, Sommerville, New Jersey, USA) was then advanced
through the implanted guide tube from its external end until —5
mm of the obturator tube appeared in the abdomen. Omentum
readily accessible for manipulation was resected to prevent
subsequent clogging of the implanted guide tube. After these
procedures, the abdominal incision was closed with a 3-0 silk.
The exteriorized catheter was tied to the surrounding skin at the
neck. The tube obturator was capped with a needle cap and
immobilized within the guide tube by applying a firm 3-0 silk
ligature around the guide tube. When animals were fully recov-
ered from anesthesia, they were returned to their cages.
Procedures of peritoneal diaLysis
During the subsequent one week period after surgical implan-
tation of guide tube, animals were made accustomed to PD
procedures by being held gently for approximately 15 minutes
two to three times every other day. All the tools used for
dialysis were sterilized by autoclave or Betadine (Purdue Fred-
erick, Norwalk, Connecticut, USA). On the day of PD, the
obturator tube was replaced by a dialysis catheter (size 8 Fr,
Dobbhoff, Biosearch), and the animals were placed in a cage
(—30 cm x —60 cm) within which they were allowed to move
freely. By infusing warmed Impersol (1.5% dextrose solution,
Abbott Laboratories) in a volume approximating 10% of body
weight into the peritoneal cavity through the dialysis catheter,
PD was initiated. PD was performed daily in sessions for eight
exchanges/day, with a 60-minute indwelling time in Group 2,
whereas no indwelling time was allowed in Group 1 control
animals. Body weight was checked at the completion of each
day of PD to ensure that dialysate had been adequately re-
moved. At the completion of the daily dialysis session, the inner
dialysis tube was replaced by a new sterile obturator tube to
prevent infection and occlusion of the implanted guide tube.
Efficacy of this PD procedure was verified by measuring Cr Of
dialysis (N = 6). The data showed that PD indeed was efficient,
achieving Cr of 0.42 0.07 ml/min during the dialysis period.
Furthermore, the typically high BUN levels immediately before
dialysis session were uniformly reduced by —50% upon com-
pletion of dialysis.
Characterization of oral adsorbent AST-120
Because of the multiple clefts on the AST-120 particles which
were engineered to drastically increase the surface area for
adsorption, attempts to quantitate various adsorbed substances
by elution have thus far been unsuccessful. To calculate the
maximum estimate of the amount of protein adsorbed by
AST-l20 and then subsequently lost in feces, the particle
density of AST-120 isolated from rat feces was measured. Five
male Munich-Wistar rats were fed standard chow (24% protein)
containing 5% wt/wt AST-120 and maintained in metabolic
cages to collect feces for four days. Feces were then dispersed
in five volumes of distilled water for one hour at room temper-
ature, and the supernatant was removed. This step was re-
peated three times. Further isolation was made by a fluidized
bed using upflow of water, sieving trays, and a tilted trough.
Finally, recovered AST-120 was dried in an oven at 105°C for
four hours, and the volume and weight were measured.
The density of recovered AST-120 was compared to that of
AST-120 before feeding. The value for the density of AST-120
before feeding was 0.801 glcc, and the values of recovered
AST-l20 from feces averaged 1.084 0.002 g/cc. Thus, AST-
120 weight gain by adsorption was 35.4%.
In the present study, Group 3 control and Group 4 AST-120
rats ate 17.6 0.5 versus 20.5 0.8 g/day (P < 0.05) of
standard rat chow or standard rat chow containing 5% AST-
120, respectively. The standard rat chow contains 24% protein,
so that the daily protein intake of Group 3 and Group 4 rats was
estimated to be, on average, 4.22 and 4.68 glday, respectively.
Average daily AST-120 intake in Group 4 rats was 1.03 g/day,
an amount estimated to adsorb 0.365 g/day of food content (that
is, 1.03 x 0.345 g/day). This latter value is smaller than the
difference in total (20.5 — 17.6 = 2.9 g/day) or protein (4.68 —
4.22 = 0.46 g/day) intake between the two groups. Overall, the
daily net calorie and protein intake of Group 4 AST-120 rats is
estimated, if any, to have been higher than that of Group 3
control rats.
The effects of AST-120 on serum levels of total protein,
albumin, triglycerides, cholesterol, calcium, and a few other
parameters in normal rats treated for six months have been
reported in Japanese literature [11]. No statistically significant
influence was observed on any of these parameters.
Micropuncture measurements
For the micropuncture measurements performed on the day
of completion of study, each animal was anesthetized with an
intraperitoneal injection of mactin (Byk, Konstanz, Germany;
100 mg/kg) and underwent preparatory surgery as previously
described [121. Thus, following tracheotomy, indwelling poly-
ethylene catheters (PE-50, Clay Adams, Parsippany, New
Jersey, USA) were placed into the left and right jugular veins
for infusion of plasma and inulin. The left femoral artery was
catheterized to monitor mean systemic arterial pressure (MAP),
which was measured using an electronic transducer (Model 5,
Instrumentation for Physiology and Medicine, San Diego, Cal-
ifornia, USA) connected to a recorder (Model 2200S, Gould
Inc., Cleveland, Ohio, USA). The left ureter was cannulated
with PE-lO tubing for subsequent collection of urine. The left
kidney was suspended on a Lucite holder, its surface illumi-
nated with a fiberoptic light source, and bathed with 0.9% NaC1.
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Table 1. Body weight and systolic blood pressure
Body weight g Systolic blood pressure mm Hg
0 week 8 weeks 12 weeks 8 weeks 12 weeks
Group 1 (N = 6) 203 4 254 II 255 11 125 6 161 10
PD control
Group 2 (N = 6) 206 5 252 6 240 9 138 7 162 8
PD
Group3(N=7) 214±2 264±5 276±4 144±8 168±7
AST- 120 control
Group 4 (N = 8) 219 4 271 7 295 l0 141 6 157 8
AST-120
Values are given as mean SE
P < 0.05 for Group 3 vs. Group 4
Volume losses due to surgical preparation were replaced with
plasma, infused in a volume equal to 1% of body weight over 30
minutes, followed by a continuous infusion at the rate of 1.2
mI/hr [13]. Following a priming dose (0.4 ml) of 5% inulin
containing 0.9% NaCI solution, a maintenance infusion of this
solution was started and continued throughout each micropunc-
ture experiment at a rate of 1.2 mI/hr. Following an equilibra-
tion period (30 mm), rats underwent assessment of glomerular
function.
Timed (—1 mm) samples of fluid were collected from the
surface proximal tubules for determination of flow rate, inulin
concentration, and calculation of tubule-to-plasma inulin con-
centration ratio, hence the single nephron glomerular filtration
rate (SNGFR). The rate of fluid collection was adjusted to
maintain a column of polymer oil, three to four tubule diameters
in length, in a constant position just distal to the site of
puncture. In conjunction with the tubule fluid collections,
femoral arterial blood samples were also obtained for the
determination of hematocrit and plasma inulin concentrations.
Urine was collected for determination of urine flow rate and
inulin concentration, which were used for the calculation of
whole kidney inulin clearance (C1). Two consecutive collec-
tions with each 10 mm duration were performed.
Hydraulic pressures were monitored in single capillaries of
surface glomeruli (0) with a continuous-recording servo-null
micropipette transducer system (Model 5, Instrumentation for
Physiology and Medicine). Micropipettes with outer tip diame-
ters of 1 to 2 em containing 2.0 M NaCI were used. Hydraulic
output from the servo-null system was converted electronically
to a recorder (Model 2200S, Gould) by means of a pressure
transducer.
Histological studies
Tissue from renal biopsy at seven weeks after subtotal
nephrectomy and the left remnant kidney obtained at the
completion of the study at 12 weeks were immersion fixed in
10% neutral-buffered formalin. After routine processing, the
specimens were embedded in paraffin, and 3 ,x serial sections
were made and stained with periodic acid-Schiff (PAS).
A semi-quantitative score (sclerosis index) was used to
evaluate the degree of glomerular sclerosis using the method of
Raij, Azar and Keane [14]. On a single thin section, 50 to 60
glomeruli for biopsy and 100 to 120 for autopsy specimens were
examined, and the severity of sclerosis was graded from 0 to 4+
for each glomerulus. The scores from all glomeruli were aver-
aged to obtain a whole kidney sclerosis index for all animals
studied. In biopsies from 12 rats, single sections contained less
than 50 glomeruli. In these animals, therefore, two separate
sections > 100 s apart (average glomerular diameter) were
examined to obtain a minimum of 50 glomeruli for analysis. A
1+ lesion represented involvement of up to 25% of the glomer-
ulus, while 4+ represented sclerosis of 75 to 100% of the
glomerulus. In Groups 1 and 2, the entire glomerular corpuscu-
lar body was also evaluated for sclerosis in randomly chosen
individual glomeruli, using 3-jxm serially sectioned specimens.
A minimum of ten sections displaying even distribution
throughout each glomerulus was examined to obtain sclerosis
index. A single score was then obtained for each glomerulus by
averaging the scores from these multiple sections. Interstitial
changes of fibrosis and tubular atrophy and dilation were
assessed qualitatively.
Analytical measurements
BUN and creatinine were measured using a BUN analyzer
(BUN Analyzer II, Beckman Instruments, Inc., Fullerton,
California, USA) and a creatinine analyzer (Creatinine Ana-
lyzer II), respectively. Serum cholesterol was measured with an
enzymatic method using a Monarch analyzer (Instrumentation
Laboratories). The volume of fluid collected from proximal
tubules by micropuncture was estimated from the length of the
fluid column in a constant-bore capillary tube of known internal
diameter. The concentration of inulin in the tubule fluid was
measured by the microfluorescence method [15]. Inulin concen-
trations in plasma and urine were determined by the macroan-
throne method [16].
Statistical analysis
Results are expressed as mean 1 SEM. Comparisons be-
tween two groups were made using the unpaired or paired
t-test, whichever was appropriate. The results were deemed
statistically significant when the P value was <0.05.
Results
Effect of peritoneal dialysis on glomerular function and
structure (Comparison between Group 1 vs. Group 2)
Values for body weight and systolic blood pressure measured
immediately before subtotal nephrectomy (0 week), at the onset
of specified therapy (8 weeks), and at the time of autopsy (12
weeks) are presented in Table 1. In Group 1 PD control and
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Table 2. BUN Ievel and whole kidney clearance
Inulin
Creatinine clearance
BUN mg/d/ clearance mi/mm mi/mm
12 weeks8 weeksa 10 weeks 10 weeksb 7 weeks 10 weeks
Group 1 (N = 6) 75 7 89 16 — 0.59 0.07 0.40 0.06 0.30 0.05
PD control
Group2(N=6) 69±6 59±6c 27±2 0.42±0.07 0.52±0.07 0.50±0.08c
PD
Group 3 (N = 7) 69 3 78 4 — 0.54 0.02 0.46 0.03 0.31 0.05
AST-120 control
Group 4 (N = 8) 68 5 74 4 — 0.61 0.05 0.47 0.02 0.39 0.04
AST- 120
Values are given as mean SE.
Values were obtained immediately before () or after (b) daily PD session
P < 0.05 for Group 1 vs. Group 2
Thus, both BUN, measured one week after biopsy at eight
weeks, and Car, at seven weeks at the time of biopsy, were
statistically indistinguishable between the two groups [BUN: 75
7 and 69 6 mg/dl in Groups 1 and 2, respectively, P not
significant (NS); C. 0.59 0.07 and 0.42 0.07 mllinin,
respectively, NS]. In Group 1 animals, in which no dialysis was
performed, BUN typically increased, on average, to 89 16
mg/dl, while Cr or C1 progressively declined. Thus, values for
C1 averaged 0.30 0.05 mI/mm at 12 weeks (Table 2). In
Group 2 dialyzed animals, values for BUN remained below
pre-biopsy levels and were significantly lower than those in
Group I at 10 weeks (89 16 vs. 59 6 mg/dl, P < 0.05). It is
apparent that this lowered BUN in Group 2 reflects not only the
function of daily peritoneal dialysis, which removes urea, but
also the intrinsic renal filtration function which was greater in
Group 2 than in Group 1 toward the end of study. Thus, C1
measured immediately before sacrifice at 12 weeks, was on
average some 67% higher in Group 2 than Group 1(0.30 0.05
0 0.2 0.4 0.6 0.8 1.0 vs. 0.50 0.08 mI/mm, P < 0.05).
Values for SNGFR and GC measured in surface nephrons at
12 weeks in Groups 1 and 2 animals are given in Figures 4 A and
B, respectively. Values for these single nephron functions
varied widely in both Group 1 and Group 2 remnant kidneys.
No statistical difference was, therefore, evident between these
two groups for either SNGFR or P0g.
Arterial blood hematocrit (N 6 in each group) and serum
cholesterol levels (N = 4 in each group) were determined at 12
weeks at the end of the study. Values for hematocrit were
comparable between PD (45 I vol %) and control groups (44
1 vol %, P > 0.1). Likewise, there was no statistically
significant difference between treated and control groups: 78.3
10.3 mg/dl versus 103.3 10.3 in Group 1 versus Group 2 (P
>0.05), respectively, and 119.6 9.2 mg/dl versus 127.3 8.1
in Group 3 versus Group 4 (P> 0.4).
Wet kidney weight measured at the completion of the study
was comparable between PD and control rats, averaging 1.43
0.10 versus 1.31 0.10 g (P > 0.1), respectively. Whole kidney
sclerosis index was obtained from biopsy (7 weeks) and autopsy
(12 weeks) specimens of the same animals and are summarized
weeks after nephrectomy in PD rats was significantly higher in Figure 5. Thus, whereas these two groups were comparable
than that of control rats (28.2 4.5 vs. 16.4 1.8 ml/24 hr, in this index at the time of biopsy, values for this index became
P < 0.05). Values for BUN and remnant kidney creatinine or substantially and significantly lower in Group 2 PD than Group
inulin clearance measured during the study are given in Table 2. 1 PD control rats (1.30 0.19 vs. 1.78 0.21, P <0.05). As can
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Fig. 3. Correlation between inulin and endogenous creatinine clear-
ance in rats with remnant kidney. Each value represents the average of
three determinations of C1,, and Cr made in each rat in a separate group
within 60 days of subtotal nephrectomy. The data show that these two
parameters correlated closely with each other (r = 0.966, P < 0.01).
Creatinine clearance, mi/rn/n
Group 2 PD animals, values for body weight were comparable
at the onset of experiment (average: 203 4 vs. 206 5 g),
increased comparably by some 25% during the eight-week
post-subtotal nephrectomy period (to 254 11 vs. 252 6 g),
and remained essentially unchanged for the remaining four
week period between biopsy and autopsy (at autopsy: 255 11
vs. 240 9 g). Values for systolic blood pressure were
numerically but not statistically significantly higher at the time
of biopsy (8 weeks) in Group 2 than Group 1(125 6 vs. 138
7 mm Hg, P> 0.05); they remained comparable at 12 weeks
(161 10 vs. 162 8 mm Hg). Urine volume assessed at 10
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Fig. 5. Whole kidney glomerular sclerosis index in Group I and Group
2 rats. Whole kidney sclerosis index was comparable between Group I
and 2 rats at biopsy. At autopsy five weeks later, there was significantly
less sclerosis in Group 2 PD versus control Group 1 rats.
be seen in Figure 5, therefore, the increase in sclerosis index,
which occurred during the five-week post-biopsy period, was
roughly three times greater in Group 1 than Group 2.
We assessed the sclerosis index at the individual glomerular
level in Group 1 PD control and Group 2 PD rats in accord with
the method described in detail elsewhere [17]. This three
dimensional approach was developed to characterize the mor-
phology of each glomerulus, since, due to the segmental nature
of the lesion, the morphological appearance of a given glomer-
ulus on a single thin-section specimen does not necessarily
represent that of its entire corpuscle. Glomeruli from biopsy
and autopsy specimens were grouped separately into four
different rankings of severity of glomerular sclerosis, the first
rank with sclerosis index 0—1, the second 1—2, the third 2—3, and
the most severe rank with 3—4, Then the percentages of glomer-
uli within each rank of glomeruli were calculated against the
total number of glomeruli examined in the biopsy. The percent
population of glomeruli with sclerosis index falling into each
rank is shown in Figure 6. Thus, whereas the percent popula-
tion of least sclerotic glomeruli (sclerosis index: 0—1) decreased
significantly from 56 14 to 20 5%, that of the most advanced
sclerosis increased significantly, on average, from 3 2 to 36
2% in control rats during the five week period. In contrast, the
pattern of percent distribution of glomeruli with variably ranked
sclerosis was essentially unchanged in PD rats from biopsy
specimen to autopsy specimen. Interstitial changes, consisting
of interstitial fibrosis and tubular atrophy and dilation, typical of
chronic renal diseases, paralleled the severity of the glomerular
lesions, with milder interstitial changes in both treated groups
compared to control. Together with the above-mentioned mark-
edly attenuated progression of glornerular sclerosis at the whole
kidney level in these rats, PD was found to be effective in
attenuating the advancement of sclerosis in glomeruli at all
stages of sclerosis.
Effect of oral adsorbent on glomerular function and structure
(Comparison between Group 3 vs. Group 4)
As shown in Table I, values for body weight of Group 4
AST-120 treated and Group 3 untreated control animals were
comparable until eight weeks. During the remaining four week
period of AST-120 treatment, values for body weight increased
in Group 4 AST-120 treated rats to a greater extent than in
Group 3 untreated control rats, averaging 276 4 versus 295
10 g at 12 weeks (P < 0.05), a finding consistent with the
observation that Group 4 AST-120 treated rats had a greater
food intake than Group 3 rats (17.6 0.5 vs. 20.5 0.7 g/day,
P < 0.05). There was no statistically significant difference
between Group 3 untreated control and Group 4 AST-120
treated rats in systolic blood pressure at the time of biopsy (144
8 and 141 6 mm Hg) or autopsy (168 7 and 157 8 mm
Hg), although Group 4 AST-120 treated rats at autopsy showed
a tendency to have lower SBP than those in Group 3 untreated
control rats. In contrast to the PD rats discussed above,
AST-120 rats had significantly lower urine volume, measured at
10 weeks, than their controls (18.2 1.7 vs. 22.4 1.0 ml124 hr,
P < 0.05). Values for BUN increased slightly and comparably
in Group 3 untreated control and Group 4 AST- 120 treated rats,
from 69 3 and 68 5 mm Hg to 78 4 and 74 4 mm Hg,
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Fig. 4. The effect of peritoneal dialysis on single
nephron GFR (SNGFR) and glomerular capillary
pressure (0) of remnant superficial nephrons, Each
circle represents the data from a single nephron. There
was no statistically significant difference in these
parameters between Group I and Group 2 rats.
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A Group 1
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Percent of total glomeruli
Autopsy
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Fig. 6. Values for percent population of glomeruli with sclerosis index
falling into four different rankings of severity. Sclerosis index was
measured three-dimensionally in individual glomeruli of Group I PD
control and Group 2 PD rats at biopsy and autopsy. The vertical scale
represents the glomerular sclerosis index. 0 being no sclerosis and 4
being complete sclerosis. Values were obtained at the time of biopsy (7
weeks) and at the completion of study (autopsy, l2 weeks). Statistical
comparison was made between biopsy and autopsy specimens from the
same animals (*P < 0.05 vs. biopsy; **, Group I, comparing
changes).
respectively, from week 8 to week 10 (Table 2). Measurement
of whole kidney filtration function, that is, Cr (measured at
biopsy and 10 weeks) and C1, (measured at 12 weeks) showed
no appreciable difference between Group 3 untreated control
and Group 4 AST-l20 treated rats. Values for hematocrit at
completion of the study were comparable between control (48
1 vol %) and AST-120-treated rats (50 2 vol %, P> 0.1).
Micropuncture measurement performed at 12 weeks showed
that values for P0c, as in Group I and 2, although varying
markedly, were significantly lower in Group 4 AST-l20 treated
than in Group 3 untreated control rats (Fig. 7B). Values for
SNGFR at 12 weeks in Group 4 AST-l20 treated rats were
lower than those in Group 3 untreated controls. The difference
was not statistically significant due in part to wide variability
within each group (Fig. 7A).
Whereas Group 3 untreated controls and Group 4 AST-l20
treated rats had comparable whole kidney sclerosis index at the
time of biopsy (0.55 0.10 vs. 0.61 0.05, P = NS: Fig. 8), this
parameter became substantially and significantly lower at 12
weeks in Group 4 AST-l20 treated than in Group 3 untreated
control rats (1.42 0.16 vs. 0.99 0.13. P < 0.05; Fig. 7).
The sclerosis index was examined in these two groups at the
individual glomerular level, as well. Virtually no glomeruli
examined in Group 3 untreated control and Group 4 AST-120
treated at biopsy had sclerosis index higher than 2.0. Thus, it
was not possible to assess the effect of AST- 120 on glomeruli at
various stages of sclerosis.
Discussion
The salutary influence of PD on glomerular structure was
paralleled by a readily discernible protection of glomerular
function. Thus, whole kidney inulin clearance rate, C1,, was
significantly higher in Group 2 PD rats than Group I control rats
at the end of the four week course of PD. Administration of oral
adsorbent, AST-l20, attenuated the progression of glomerular
sclerosis to a degree comparable to that of PD. Thus, our
observation with this oral charcoal adsorbent echoes the earlier
findings by Kanai et al [18] and Yoshida et al [19]. The increases
in sclerosis index from biopsy to autopsy specimens in Group 4
rats given AST-l20, as well as Group 2 PD-treated rats, were
less than half of those found in their corresponding untreated
control groups, that is, Group 3 and Group 1, respectively.
Nevertheless, unlike Group 2 PD-treated animals, no apprecia-
ble salutary effect of AST-l20 was demonstrated on glomerular
filtration rate in Group 4 animals (Table 2). This variation may
be readily explained when one considers that both of these
therapeutic measures potentially affect at least two of the
opposing parameters determining glomerular filtration rate.
Thus, their capability to protect glomeruli from sclerosis, hence
from loss of filtration surface area, may serve to preserve
filtration function. However, lower glomerular capillary pres-
sure is expected to promote reduction in GFR. In this regard,
unlike PD, AST-120 did suppress glomerular capillary pressure.
This suppression, therefore, appears to be sufficiently profound
to offset the salutary effect on the glomerular structure that
would otherwise be expected to result in higher GFR in Group
4 AST-l20 treated than Group 3 untreated animals at the
completion of study. It is likely that this apparent difference in
the effect of PD versus AST-120 on P0c reflects, at least in part,
differences in their effect on the external balance of salt and
water as well as nutrients. Nevertheless, the marked nephron-
to-nephron variability in glomerular pressures and flows pre-
vailing in this model of chronic renal failure [12] precluded
assessment of other single glomerular hemodynamic parame-
ters which may also account for this difference between the two
groups. The observed comparable GFR values between Groups
1 and 3, despite higher P0 and an apparently lower degree of
sclerosis in Group 3 than in Group 1, also remain undetermined.
The observed effects of PD and AST-120 result not only from
the intrinsic capacity of dialysis and adsorbent to remove
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Fig. 8. Whole kidney glomerular sclerosis index in Group 3 and Group
4 rats. Whole kidney sclerosis index was comparable between Group 3
and Group 4 rats at biopsy. At autopsy five weeks later, there was
significantly less sclerosis in Group 4 AST-120 rats versus control
Group 3.
various metabolites but also from their influence on the animals'
dietary habits. Unlike PD, AST-120 per se has virtually no
capacity to remove water. Moreover, AST-120, unlike PD,
promoted food intake in animals, as Group 4 animals, given
AST-120, had significantly greater food intake and body weight
gain than Group 3 control animals. In contrast, Group 2
PD-treated and Group 1 untreated rats had comparable body
weight gains.
Given the notion, derived from experimental observations in
the parabiotic system and other animal models [1, 20, 21], that
Fig. 7. The effect of oral adsorbent AST-120 on single
nephron GFR (SNGFR) and glomerular capillary
pressure (Gc) of remnant superficial nephrons. Each
circle represents the data from a single nephron. There
was no statistically significant difference in the values of
SNGFR between Group 3 control and Group 4 AST-120
rats. The values for Gc in Group 4 rats were
significantly lower than those in Group 3 rats (P <
0.05).
the hypertrophy of remnant nephrons following nephrectomy
involves circulating substances and that the phenomenon of
glomerular hypertrophy and sclerosis are closely linked [11,
22—24], the series of findings in the current study are hardly
surprising. Thus, the circulating substances which have the
capacity to promote glomerular hypertrophy and sclerosis may
accumulate in the body following substantial loss of functioning
nephrons. Furthermore, both dialysis and oral adsorbent AST-
120, by replacing the renal function of removing such circulat-
ing substances, attenuate the glomerular hypertrophy and scle-
rosis. As dialysis essentially replaces only the glomerular
filtration function of the removed nephrons, the substances
concerned appear ultrafiltrable in nature. The oral adsorbent
AST- 120 does not have capacity to adsorb water but, instead,
promotes net food intake and body weight gain. Therefore, of
the ultrafiltrable substances that PD could remove from the
circulation, substances such as water, salt or nutrients, are
unlikely candidates.
Of note, the possibility exists that the circulating substances
involved in hypertrophy and/or sclerosis could be inhibitors of
glomerular growth and sclerosis. Nephron loss would then lead
to suppression of the production of such circulating inhibitory
substances. However, our observations negate this possibility,
since it appears highly unlikely that dialysis or AST-120, with
their biologically inert constituents, could replace the hypothet-
ical nephron function of releasing biologically-active inhibitory
substances. Thus, our observations support the notion that
nephrectomy increases circulating levels of stimulatory, rather
than reducing inhibitory, substances affecting growth and scle-
rosis. Furthermore, it has become apparent that the circulating
substance(s) are not BUN or creatinine per se, as these two
parameters were comparable between Group 4 AST- 120 treated
and Group 3 untreated animals.
It should be noted that the circulating substances, in and of
themselves, may or may not have the potential to promote
glomerutar hypertrophy or sclerosis. If they do, they are clearly
not among currently known growth factors, since these growth
factors lack specificity for effects on the kidney. Alternatively,
the kidney may have a selective high affinity for the circulating
substances, which in turn evoke local release of growth factors,
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known or unknown, in an autocrine or paracrine fashion. Of
note, the circulating substances under discussion should, in no
way, be considered an alternative to any of the variety of local
pathogenic mechanisms proposed today. Since training the rats
and establishing and maintaining a close kinship between the
investigator and the rats were prerequisite for the successful
conduct of dialysis, a few parameters were collected, mostly at
the time of sacrifice, clearly precluding any conclusion on the
currently debated local mechanisms. Instead, our results point
to a pathophysiologic significance of "uremic toxins" as a
mechanism capable of provoking the debated local mecha-
nisms.
Collectively, we speculate on the possible mechanism of the
progression of glomerular sclerosis: The initial pathogenic
insults lead to a loss of functioning nephrons through disease-
specific pathophysiologic processes resulting in increased levels
of circulating substances. These substances promote the pro-
duction of mesangial matrix, which per Se is self-damaging in
nature, by provoking a series of local pathogenic mechanisms
leading to further loss of nephrons. This loss of nephrons, in
turn, causes accumulation in the circulation of the substance(s)
capable of causing compensatory glomerular hypertrophy and
sclerosis. The ultimate outcome of this vicious cycle is the end
stage kidney. Removal of circulating substances by peritoneal
dialysis or oral adsorbent disrupts this vicious cycle, thereby
exerting a protective effect on intact glomeruli against progres-
sive structural deterioration.
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